Inflammatory, immune, and viral aspects of inclusion-body myositis

被引:62
作者
Dalakas, MC [1 ]
机构
[1] NINDS, Neuromuscular Dis Sect, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1212/01.wnl.0000192129.65677.87
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Muscle biopsies from patients with sporadic inclusion-body myositis (sIBM) consistently demonstrate that the inflammatory T cells almost invariably invade intact ( not vacuolated) fibers, whereas the vacuolated fibers are rarely invaded by T cells. This indicates two concurrently ongoing processes, an autoimmune mediated by cytotoxic T cells and a degenerative manifested by the vacuolated muscle fibers and deposits of amyloid-related proteins. The autoimmune features of IBM are highlighted by the strong association of the disease with: a) HLA I, II antigens, in frequency identical to classic autoimmune diseases; b) other autoimmune disorders in up to 32% of the patients, autoantibodies, paraproteinemias, or immunodeficiency; c) HIV and HTLV-I infection with increasingly recognized frequency (up to 13 known cases); and d) antigen-specific, cytotoxic, and clonally expanded CD8+ autoinvasive T cells with rearranged T-cell receptor genes that persist over time, even in different muscles, and invade muscle fibers expressing MHC-I antigen and costimulatory molecules. In contrast to IBM, in various dystrophies the inflammatory cells are clonally diverse and the muscle fibers do not express MHC-I or costimulatory molecules in the pattern seen in IBM. Like other chronic autoimmune conditions with coexisting inflammatory and degenerative features (i.e., primary progressive MS), IBM is resistant to conventional immunotherapies. Recent data suggest that strong anti-T cell therapies can be promising and they are the focus of ongoing research.
引用
收藏
页码:S33 / S38
页数:6
相关论文
共 50 条
[21]   Proteasornal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis [J].
Ferrer, I ;
Martín, B ;
Castaño, JG ;
Lucas, JJ ;
Moreno, D ;
Olivé, M .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2004, 63 (05) :484-498
[22]   Coexistence of X-linked recessive Emery-Dreifuss muscular dystrophy with inclusion body myositis-like morphology [J].
Fidzianska, A ;
Rowinska-Marcinska, K ;
Hausmanowa-Petrusewicz, I .
ACTA NEUROPATHOLOGICA, 2004, 107 (03) :197-203
[23]   Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies [J].
Figarella-Branger, D ;
Civatte, M ;
Bartoli, C ;
Pellissier, JF .
MUSCLE & NERVE, 2003, 28 (06) :659-682
[24]   Oligoclonal expansion of muscle infiltrating T cells in inclusion body myositis [J].
Fyhr, IM ;
Moslemi, AR ;
Mosavi, AA ;
Lindberg, C ;
Tarkowski, A ;
Oldfors, A .
JOURNAL OF NEUROIMMUNOLOGY, 1997, 79 (02) :185-189
[25]   INCLUSION-BODY MYOSITIS AND MYOPATHIES [J].
GRIGGS, RC ;
ASKANAS, V ;
DIMAURO, S ;
ENGEL, A ;
KARPATI, G ;
MENDELL, JR ;
ROWLAND, LP .
ANNALS OF NEUROLOGY, 1995, 38 (05) :705-713
[26]   EXPRESSION OF IMMUNOREACTIVE MAJOR HISTOCOMPATIBILITY COMPLEX PRODUCTS IN HUMAN SKELETAL-MUSCLES [J].
KARPATI, G ;
POULIOT, Y ;
CARPENTER, S .
ANNALS OF NEUROLOGY, 1988, 23 (01) :64-72
[27]  
Koffman BM, 1998, MUSCLE NERVE, V21, P115, DOI 10.1002/(SICI)1097-4598(199801)21:1<115::AID-MUS15>3.3.CO
[28]  
2-G
[29]   HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies [J].
Koffman, BM ;
Sivakumar, K ;
Simonis, T ;
Stroncek, D ;
Dalakas, MC .
JOURNAL OF NEUROIMMUNOLOGY, 1998, 84 (02) :139-142
[30]   Anti-T-lymphocyte globulin treatment in inclusion body myositis - A randomized pilot study [J].
Lindberg, C ;
Trysberg, E ;
Tarkowski, A ;
Oldfors, A .
NEUROLOGY, 2003, 61 (02) :260-262